Table 3. Evaluation of predictive value of DCR1 methylation on progression after treatment(multivariate cox proportional hazard model).
| Variables in the model | CAIRO discovery set | CAIRO validation set | FOCUS validation set | |||
|---|---|---|---|---|---|---|
| HR | p-value | HR | p-value | HR | p-value | |
| Treatment | 0.4 | 0.00002 | 0.4 | 0.0001 | 0.9 | 0.4 |
| DCR1 methylation status | 0.6 | 0.05 | 0.8 | 0.3 | 1.1 | 0.6 |
| Age | 1.0 | 0.8 | 1.0 | 0.03 | 1.0 | 0.05 |
| Gender | 0.7 | 0.05 | 1.0 | 0.9 | 0.9 | 0.5 |
| WHO performance status | 1.1 | 0.5 | 1.1 | 0.5 | 1.0 | 0.8 |
| Previous adjuvant therapy | 1.5 | 0.04 | 1.2 | 0.5 | 1.1 | 0.6 |
| LDH | 1.7 | 0.002 | 1.5 | 0.02 | na | na |
| location of metastases | 1.4 | 0.07 | 0.8 | 0.2 | na | na |
| Interaction treatment*DCR1 methylation status | 2.9 | 0.0008 | 2.0 | 0.04 | 0.8 | 0.3 |
HR = hazard ratio